Jump to main content
Jump to site search
Access to RSC content Close the message box

Continue to access RSC content when you are not at your institution. Follow our step-by-step guide.


Issue 6, 2014
Previous Article Next Article

The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

Author affiliations

Abstract

Atovaquone is a front-line antimalarial drug that functions by competitively inhibiting binding of coenzyme Q10 to the cytochrome bc1 complex. Atovaquone is administered orally, but has low solubility and is poorly absorbed with high variability in bioavailability. In vivo binding of human serum albumin has been cited as the major transporter of atovaquone in plasma. The research presented herein demonstrates that saposin B, a known binder/transporter of coenzyme Q10, also binds to atovaquone in a 1 : 1 ratio and with comparably high affinity at pH 5.5.

Graphical abstract: The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

Back to tab navigation

Article information


Submitted
06 Dec 2013
Accepted
25 Feb 2014
First published
05 Mar 2014

Med. Chem. Commun., 2014,5, 787-791
Article type
Concise Article
Author version available

The antimalarial drug atovaquone binds to saposin B with comparable affinity to coenzyme Q10

B. P. Huta, A. M. Roberts, E. S. Waters, V. Y. Yu, R. P. Doyle, M. R. Mehlenbacher and F. Bou-Abdallah, Med. Chem. Commun., 2014, 5, 787
DOI: 10.1039/C3MD00373F

Search articles by author

Spotlight

Advertisements